SpyGlass Pharma, a late-stage biopharmaceutical company, announced encouraging results from two clinical trials of its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), offering a potential breakthrough for patients with mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT).

The data, presented at the Interventional Glaucoma Consortium in Salt Lake City, highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance—marking a significant milestone for both the company and patients seeking long-term disease control without the burden of daily eye drops.

The data included 36-month follow-up data from the FIH trial and three-month interim safety and efficacy results from the Phase I/II trial, the company said in a release.

“The FIH results demonstrate that the BIM-IOL System can deliver sustained IOP reduction, drop-free outcomes, and strong visual performance for three years,” said Malik Kahook, co-founder and president of SpyGlass Pharma.

“Our Phase I/II trial aims to confirm these findings across a larger patient population and has shown similar IOP reduction and drop-free outcomes three months after implantation. Together, these results represent an important milestone for both SpyGlass and patients in need of disease control while removing the adherence burden.”

"The physician community needs better sustained drug delivery options to eliminate the adherence burden of IOP-lowering drops for patients with open-angle glaucoma or ocular hypertension," said Jeffrey Kammer, associate professor of ophthalmology at Vanderbilt University Medical Center and an investigator in the Phase I/II trial.

"The implantation procedure during routine cataract surgery is straightforward, and the three-month IOP reduction results and improved visual performance are highly compelling. I am excited to continue to work with SpyGlass to monitor longer-term results of the BIM-IOL System.”